Time to boost COVID-19 vaccine manufacturing: The need for intellectual property waiver by big pharma-Reference-Cited by-同舟云学术

Time to boost COVID-19 vaccine manufacturing: The need for intellectual property waiver by big pharma

Published:2021-12 Issue: Volume:19 Page:100710
ISSN:2352-5525
Container-title:Ethics, Medicine and Public Health
language:en
Short-container-title:Ethics, Medicine and Public Health

Author:

Okereke M.,Essar M.Y.

Publisher

Elsevier BV

Subject

Health Policy

Reference20 articles.

1. COVID-19 vaccines: how to ensure Africa has access;Nkengasong;Nature,2020

2. South Africa and India push for COVID-19 patents ban;Usher;Lancet,2020

3. The COVID-19 vaccine patent waiver: a crucial step towards a “people's vaccine”;Gonsalves;BMJ,2021

4. World Trade Organization. Members to continue discussion on proposal for temporary IP waiver in response to COVID-19. https://www.wto.org/english/news_e/news20_e/trip_10dec20_e.htm Accessed 26 June 2021.

5. US Support for a WTO waiver of COVID-19 intellectual property;Contreras;Inter Econ,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of Chinese vaccine diplomacy during COVID-19 in the Philippines and Vietnam: a multiple case study from a soft power perspective;Humanities and Social Sciences Communications;2023-10-11

2. The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities;Terra Economicus;2023-09-25

3. Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market;Pharmaceutical Patent Analyst;2022-09

4. Vaccines (I): Creation and Distribution;The Ethical, Legal and Social Issues of Pandemics;2022

5. Second wave of COVID‐19 in Nigeria: Lessons from the first wave;The International Journal of Health Planning and Management;2021-12-02